Search results
Results from the WOW.Com Content Network
In this article we will take a look at whether hedge funds think Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a good investment right now. We check hedge fund and billionaire investor sentiment ...
The Center for Research in Security Prices, LLC (CRSP) is a provider of historical stock market and investable index data. CRSP is an affiliate of the Booth School of Business at the University of Chicago. CRSP maintains some of the largest and most comprehensive proprietary historical databases in stock market research.
Alnylam (ALNY) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes. Alnylam (ALNY) Catches Eye: Stock Jumps 10.5% Skip to main content
Alnylam (ALNY) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Alnylam still does not earn money, but writes losses. The losses ("GAAP Operating Loss") from Alnylam were around $650 million in the late 2020. Alnylam expects to achieve net profits financially in 2022 or 2023. [40] In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension ...
Will be right back... Thank you for your patience. Our engineers are working quickly to resolve the issue.
For premium support please call: 800-290-4726 more ways to reach us